Risankizumab

Therapeutic Risankizumab antibody from the original Skyrizi® commercial drug

Showing the single result

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price
IL-23
Monoclonal Antibody
Skyrizi®
90 mg/mL
yes
4 mg
-80°C
06/2021
894,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Risankizumab?

Search our therapeutic molecules product database

Skyrizi® / Risankizumab Reference Product

Drug nameSkyrizi®
INNRisankizumab
API typeRisankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
Pharmacotherapeutic group
Immunosuppressants, interleukin inhibitors.
ATC code
L04AC18
Target of antibody
IL-23
General functionRisankizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are
candidates for systemic therapy.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds
with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab
inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was
decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.
Original license holder
AbbVie Biotechnology GmbH
Knollstrasse
67061 Ludwigshafen
Germany
Marketing authorisation numbers
EU/1/19/1361/001
Marketing authorisation holder
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Str. 65
88397 Biberach a.d.R.
GERMANY
and
AbbVie Bioresearch Center Inc.
100 Research Drive
Worcester
MA 01605
USA
Name and address of the manufacturer(s) responsible for batch releaseAbbVie S.r.l.
148, Pontina Km 52 snc
04011
Campoverde di Aprilia (LT)
ITALY
and
AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
GERMANY
Max shelf life
24 months
Storage conditions
2°C – 8°C
List of excipients
Disodium succinate hexahydrate
Succinic acid
Sorbitol
Polysorbate 20
Water for injections
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.

we are recruiting